[High risk group for development of hepatocellular carcinoma].
Koike
Y
Y
Department of Gastroenterology, Faculty of Medicine, University of Tokyo.
Shiratori
Y
Y
D015415:Biomarkers; D014408:Biomarkers, Tumor / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D011498:Protein Precursors / Q000097:blood; D011516:Prothrombin; D012306:Risk; D000509:alpha-Fetoproteins / Q000032:analysis
D015415:Biomarkers; D014408:Biomarkers, Tumor; D011498:Protein Precursors; D000509:alpha-Fetoproteins; C008208:acarboxyprothrombin; D011516:Prothrombin; D007372:Interferons